Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 90 of 90 entries
View as:

ICG-fluorescence Imaging for Intraoperative Breast Cancer Margins Evaluation: a Dose-timing Study

Phase: N/A Priority: Normal
NCT ID: NCT06227338 Org: User:
Start: 02/12/24 End: 01/01/26 Due: 01/01/27

Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04856475 Org: User:
Start: 11/24/21 End: 11/24/21 Due: 11/24/22

Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01537536 Org: User:
Start: 11/30/11 End: 11/30/12 Due: 11/30/13

Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01916837 Org: User:
Start: 02/28/10 End: 12/31/10 Due: 12/31/11

Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00398437 Org: User:
Start: 09/30/06 End: - Due: -

Study of the ICG Distribution in Breast Tumours or in Axillary Lymph Nodes of Patients After Neoadjuvant Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02032563 Org: User:
Start: 12/31/13 End: 10/31/14 Due: 10/31/15

A Mixed Method to Study Adherence to Oral Anticancer Medications in a Multilingual and Multicultural Setting

Phase: N/A Priority: Normal
NCT ID: NCT04613765 Org: User:
Start: 12/01/20 End: 02/28/22 Due: 02/28/23

Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:

Phase: N/A Priority: Normal
NCT ID: NCT03875573 Org: User:
Start: 11/06/19 End: 09/30/29 Due: 09/30/30

Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)

Phase: N/A Priority: Normal
NCT ID: NCT03065621 Org: User:
Start: 07/05/17 End: 02/01/23 Due: 02/01/24

Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer

Phase: N/A Priority: Normal
NCT ID: NCT02338531 Org: User:
Start: 06/30/15 End: 12/31/18 Due: 12/31/19

Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01709487 Org: User:
Start: 05/31/10 End: 10/31/15 Due: 10/31/16

Study of the ICG Distribution in the Margins of Breast Cancer After Tumorectomy

Phase: N/A Priority: Normal
NCT ID: NCT02027818 Org: User:
Start: 01/31/14 End: 10/31/14 Due: 10/31/15

177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs

Phase: N/A Priority: Normal
NCT ID: NCT01842165 Org: User:
Start: 05/31/13 End: 09/19/22 Due: 09/19/23

Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC

Phase: N/A Priority: Normal
NCT ID: NCT03616886 Org: User:
Start: 12/28/18 End: 12/31/25 Due: 12/31/26

Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)

Phase: N/A Priority: Normal
NCT ID: NCT03674424 Org: User:
Start: 06/01/18 End: 01/30/25 Due: 01/30/26